22 completed, 1 terminated. 12 Phase 3, 6 Phase 2, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 11, Terminated 1 |
| Phase 2 | 6 | Completed 6 |
| Phase 4 | 2 | Completed 2 |
Follow pentacel: new trials by email Literature Review of pentacel trials Research Report on pentacel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine - RSV Immunization | Phase 3 | Terminated | Sanofi Pasteur, a Sanofi Company | 2226 | 2024-05-13 | 2026-10-05 |
| Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3 - Pneumococcal Immunisation, Diphtheria Immunisation | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 852 | 2020-05-22 | 2025-09-08 |
| Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) V114, Prevnar 13™, RotaTeq™ - Pneumococcal Infections, Pneumococcal Vaccines | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1720 | 2019-06-19 | 2023-07-28 |
| A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION) Prevnar 13™, V114, RotaTeq™ - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 900 | 2018-10-18 | 2023-01-17 |
| Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US MenACYW conjugate vaccine, MenACYW-135 conjugate vaccine, DTaP-IPV//Hib vaccine - Healthy Volunteers (Meningococcal Infection) | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 2627 | 2018-04-25 | 2024-10-15 |
| Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants Infanrix hexa, Pediarix, ActHIB - Poliomyelitis, Diphtheria | Phase 3 | Completed | GlaxoSmithKline | 585 | 2014-04-16 | 2019-11-27 |
| Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Meningococcal polysaccharide diphtheria toxoid conjugate, Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate - Meningitis, Meningococcal Infection | Phase 4 | Completed | Sanofi Pasteur, a Sanofi Company | 1394 | 2012-07-01 | 2015-12-15 |
| A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006) V419, PENTACEL™, Prevnar 13™ - Bacterial Infections, Virus Diseases | Phase 3 | Completed | Merck Sharp & Dohme LLC | 2808 | 2011-05-10 | 2018-11-15 |
| Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005) V419, DAPTACEL™, PedvaxHIB™ - Bacterial Infections, Virus Diseases | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1473 | 2011-04-19 | 2018-11-15 |
| Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108), ActHIB™, Pentacel™ - Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 4003 | 2010-06-18 | 2018-07-12 |
| Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines Pentacel® (DTaP-IPV/Hib), Other Pertussis Vaccines - Pertussis | Completed | Sanofi Pasteur, a Sanofi Company | 1195 | 2010-02-08 | 2022-04-25 | |
| A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined), M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live - Meningitis, Meningococcal Infection | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 580 | 2009-12-16 | 2022-03-28 |
| A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months MenACWY-CRM, DTaP-IPV/Hib, HBV - Meningococcal Disease | Phase 3 | Completed | Novartis Vaccines | 529 | 2009-11-01 | 2014-04-21 |
| Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease DTaP-IPV/Hib - Haemophilus Infections, Diphtheria | Completed | Sanofi Pasteur, a Sanofi Company | 20830 | 2009-02-01 | 2022-04-25 | |
| Database Surveillance Safety Study of PENTACEL® Vaccine DTaP-IPV/Hib, Other DTap Vaccines - Diphtheria, Tetanus | Completed | Sanofi Pasteur, a Sanofi Company | 62538 | 2008-09-01 | 2015-08-19 | |
| Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar® Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC - Diphtheria, Pertussis | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 460 | 2006-08-01 | 2014-01-14 |
| Does the Order in Which Vaccines Are Administered Affect Pain Response? Pentacel (DPTaP+Hib), Prevnar (conjugated pneumococcal vaccine) - Pain | Phase 4 | Completed | The Hospital for Sick Children | 120 | 2006-07-01 | 2013-11-13 |
| Safety and Immune Response of Different Pediatric Combination Vaccines. DAPTACEL®. (DTaP), IPOL®., and ActHIB®., Pentacel®: DTaP-IPV/Hib combined, DTaP-IPV and ActHIB® - Diphtheria, Polio | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 2167 | 2005-11-01 | 2014-02-14 |
| Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months) MenACWY-CRM, MenC-CRM, DTaP-Hib-IPV - Meningococcal Meningitis | Phase 2 | Completed | Novartis Vaccines | 175 | 2005-06-01 | 2018-10-09 |
| Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™ Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar® - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi | 1167 | 2003-10-01 | 2012-02-01 |
Showing 20 of 23. Sign in to see all of them.
Diphtheria (10) · Haemophilus Infections (10) · Tetanus (10) · Whooping Cough (10) · Poliomyelitis (8) · Hepatitis B (4) · Meningococcal Infections (4) · Bacterial Infections (3) · Meningitis (3) · Virus Diseases (3) · Meningitis, Meningococcal (2) · Pneumococcal Infections (2) · Gram-Negative Bacterial Infections (1) · Pain (1) · Rotavirus Infections (1)
Sanofi Pasteur, a Sanofi Company (10) · Merck Sharp & Dohme LLC (5) · GlaxoSmithKline (3) · Novartis Vaccines (2) · Sanofi (2) · The Hospital for Sick Children (1)
United States (16) · Puerto Rico (6) · Canada (5) · Thailand (2) · Turkey (Türkiye) (2) · Australia (1) · Honduras (1) · Mexico (1)
Francisco Diaz-Mitoma, Dr. (1) · Moshe Ipp, MD (1) · Scott Halperin, Dr. (1)
PMID 19117896, PMID 19414694, PMID 21134456, PMID 22475857, PMID 23241989, PMID 24346596, PMID 25156560, PMID 27373595, PMID 27846058, PMID 32921507, PMID 35144847, PMID 36522265, PMID 36621410, PMID 37846456, PMID 41337697
2018 (3)